Circulating Nesfatin-1 Levels and Type 2 Diabetes: A Systematic Review and Meta-Analysis

Table 2

Summary risk estimates of circulating nesfatin-1 levels and type 2 diabetes mellitus.

	Studies	Random effects SMD (95% CI)	I^2 (%)	P for heterogeneity
Overall	7	−0.16 (−0.57, 0.24)	98	<0.00001
Subgroup analysis
Age
<55	3	0.00 (−0.41, 0.42)	94	<0.00001
≥55	4	−0.08 (−0.53, 0.37)	96	<0.00001
BMI
<25	2	−0.25 (−0.36, 0.13)	0	<0.0001
≥25	5	−0.04 (−0.36, 0.44)	96	<0.00001
HOMA-IR ratio
<4	3	0.29 (−0.37, 0.95)	98	<0.00001
≥4	2	−0.23 (−0.34, −0.12)	0	0.91
Unknown	2	−0.32 (−0.53, −0.11)	33	0
Blood sample
Plasma	4	−0.03 (−0.11, 0.05)	0	0.98
Serum	3	−0.24 (−0.33, −0.15)	97	<0.00001
T2D criteria
WHO	4	0.16 (−0.31, 0.63)	97	<0.00001
ADA	3	−0.26 (−0.36, −0.16)	0	0.39
Study type
Case-control	4	−0.08 (−0.53, 0.37)	96	<0.00001
Cross-sectional	3	0.00 (−0.41, 0.41)	94	<0.00001
Study quality
Good	6	−0.01 (−0.35, 0.33)	96	<0.00001
Moderate	1	—	—	—